Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Stephen Miller, Trump's deputy chief of staff for policy and key architect of the administration's immigration enforcement strategy, faces questions about continuing aggressive deportation campaigns ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

RXRX is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has increased $0.13 since the market last closed. This is a 3.83 ...

So, you’re looking to get better at coding interviews, huh? Maybe you’ve heard about LeetCode and feel a bit lost. It’s ...